Venlafaxine
It in humans is believed to be associated with its potentiation of neurotransmitter activity in the CNS.Treatment of depression and extended release venlafaxine is indicated for the treatment of generalized anxiety disorder.
Depresion 75mg/day administered in two or three divided doses or as a single dose. Generalized anxiety disorder, 75mg/day, administered in a single dose.
Hypersensitivity, concomitant use in patients taking monoamine oxidase inhibitors (MAOIs).
Seizures, mania and with disease or conditions that could affect haemodynamic responses or metabolism.
Nausea, headache, asthenia, sweating, dizziness and isomnia.